Given the multifaceted nature of AD pathogenesis, future treatments need to adopt a multimodal approach that targets the Aβ-tau signaling pathway via the modulation of the PI3K/AKT/GSK3β signaling cascade, leading to a pro-neuroplastic effect via enhanced BDNF signaling. This evidence concerns the gene BDNF and Alzheimer disease.